Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker and the Genome British Columbia Proteomics Centre to Collaborate

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.

Diabetes: The liquid chromatography, immunoassay and electrophoresis-based methods which are currently used to screen and monitor for blood disorders are expensive, laborious and time-consuming. In 2009, the Expert Committeeof the International Diabetes Foundation recommended the use of the hemoglobin-based A1c (hbA1c) test as the “method of choice” for diagnosing and monitoring diabetes. In contrast to previous assays, it is expected that the new MALDI (Matrix-Assisted Laser Desorption Ionization) TOF-MS (time-of-flight mass spectrometry) based test for hbA1c and genetic hemoglobin variants designed for use on theMALDI Biotyper platform will provide advantages with regards to specificity, accuracy, speed of analysis and cost per analysis. These performance and cost advantages, coupled with the ease of use and speed of a MALDI-TOF assay, are anticipated to result in higher patient screening rates, which is especially important in the case of diabetes where early detection of at-risk subjects can lead to the prevention of disease onset. Complications of undiagnosed or poorly controlled diabetes include cardiovascular disease, chronic renal failure, retinal damage which can lead to blindness, several kinds of nerve damage, and micro-vascular damage.

Hemoglobin Variants: Some well-known genetic hemoglobin variants are responsible for diseases such as sickle-cell anemia, C disease, and a separate class of diseases known as thalassemias. Diabetes is also reflected in the blood by an increase in the level of glycated hemoglobin, which is measured in the hbA1c test. In general, individuals with inherited blood disorders are physiologically vulnerable and are at higher risk of infection, stroke, heart failure, liver and acute chest syndrome. Late diagnosis of diseases such as sickle-cell anemia can result in delay of treatment and irreversible damage to major organs, including increased risk of stroke or kidney damage.

The MALDI Biotyper platform is already in widespread clinical use with over 800 systems installed globally. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in various European countries, and as a Class 1 Medical Device to clinical microbiology sites in Canada. In the United States of America the MALDI Biotyper is available for research use only, not for use in diagnostic procedures.

Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics, stated: “The MALDI Biotyper is a versatile, robust, benchtop system that is well suited for use in clinical laboratories as evidenced by its large installed base. We are very pleased to be working with the world-class team of researchers at the UVic GBC Proteomics Centre on the development and validation of high throughput iMALDI tests to further broaden the clinical applications of the MALDI Biotyper platform.”

Professor Christoph Borchers, Director of the GBC UVic Proteomics Centre, commented: “The collaboration with Bruker is an excellent match. We believe that further development of our MALDI and immunoMALDI (iMALDI) technology will lead to commercialization of MALDI-TOF based tests for a number of important diseases. Developing and validating these tests in collaboration with Bruker gives us a partner ready to deploy such tests on the clinically accepted MALDI Biotyper platform, which will reduce our time to market.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.
Friday, January 04, 2013
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker and Berkeley Lab Collaborate on Novel Technology for Structural Biology
Berkeley Lab and Bruker intend to integrate SAXS and NMR data for 3D structure determination of multi-domain proteins and protein complexes with DNA, RNA or other proteins.
Thursday, November 24, 2011
Scientific News
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
X-ray Laser Experiment Could Help in Designing Drugs for Brain Disorders
Scientists found that when two protein structures in the brain join up, they act as an amplifier for a slight increase in calcium concentration, triggering a gunshot-like release of neurotransmitters from one neuron to another.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Why We’re Smarter Than Chickens
Toronto researchers have discovered that a single molecular event in our cells could hold the key to how we evolved to become the smartest animal on the planet.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!